Renaissance Group LLC lowered its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 3.7% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 387,131 shares of the biopharmaceutical company’s stock after selling 14,705 shares during the period. Renaissance Group LLC’s holdings in Gilead Sciences were worth $27,734,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Dorsey & Whitney Trust CO LLC grew its position in Gilead Sciences by 28.3% during the 2nd quarter. Dorsey & Whitney Trust CO LLC now owns 9,505 shares of the biopharmaceutical company’s stock worth $673,000 after purchasing an additional 2,096 shares in the last quarter. Rock Point Advisors LLC grew its position in Gilead Sciences by 2.9% during the 2nd quarter. Rock Point Advisors LLC now owns 123,777 shares of the biopharmaceutical company’s stock worth $8,761,000 after purchasing an additional 3,472 shares in the last quarter. Bahl & Gaynor Inc. grew its position in Gilead Sciences by 4.1% during the 2nd quarter. Bahl & Gaynor Inc. now owns 24,530 shares of the biopharmaceutical company’s stock worth $1,756,000 after purchasing an additional 974 shares in the last quarter. Letko Brosseau & Associates Inc. grew its position in Gilead Sciences by 0.8% during the 2nd quarter. Letko Brosseau & Associates Inc. now owns 1,391,826 shares of the biopharmaceutical company’s stock worth $98,513,000 after purchasing an additional 10,477 shares in the last quarter. Finally, BlackRock Inc. grew its position in Gilead Sciences by 1.9% during the 2nd quarter. BlackRock Inc. now owns 104,906,494 shares of the biopharmaceutical company’s stock worth $7,425,281,000 after purchasing an additional 1,937,031 shares in the last quarter. 77.83% of the stock is currently owned by institutional investors.

How to Become a New Pot Stock Millionaire

Several equities analysts have weighed in on the stock. ValuEngine upgraded shares of Gilead Sciences from a “buy” rating to a “strong-buy” rating in a research report on Thursday, February 8th. Credit Suisse Group set a $80.00 price objective on shares of Gilead Sciences and gave the stock a “hold” rating in a research report on Wednesday, January 3rd. Leerink Swann lowered their price objective on shares of Gilead Sciences from $86.00 to $83.00 and set a “market perform” rating on the stock in a research report on Wednesday, February 7th. Vetr upgraded shares of Gilead Sciences from a “buy” rating to a “strong-buy” rating and set a $91.25 price objective on the stock in a research report on Monday, February 19th. Finally, Barclays reiterated an “overweight” rating and set a $95.00 price objective (up from $90.00) on shares of Gilead Sciences in a research report on Tuesday, March 6th. One equities research analyst has rated the stock with a sell rating, ten have issued a hold rating, seventeen have given a buy rating and two have issued a strong buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $88.61.

In related news, CFO Robin L. Washington sold 5,000 shares of the company’s stock in a transaction on Wednesday, February 28th. The shares were sold at an average price of $80.31, for a total value of $401,550.00. Following the completion of the sale, the chief financial officer now directly owns 23,749 shares in the company, valued at $1,907,282.19. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director John Francis Cogan sold 5,833 shares of the company’s stock in a transaction on Friday, March 16th. The stock was sold at an average price of $80.09, for a total transaction of $467,164.97. Following the completion of the sale, the director now owns 58,452 shares of the company’s stock, valued at $4,681,420.68. The disclosure for this sale can be found here. Insiders sold 436,101 shares of company stock valued at $34,541,560 over the last quarter. 1.30% of the stock is currently owned by corporate insiders.

Shares of Gilead Sciences stock opened at $76.49 on Thursday. The stock has a market cap of $100,762.73, a price-to-earnings ratio of 21.98, a P/E/G ratio of -1.77 and a beta of 1.24. Gilead Sciences, Inc. has a fifty-two week low of $63.76 and a fifty-two week high of $89.54. The company has a quick ratio of 2.67, a current ratio of 2.74 and a debt-to-equity ratio of 1.53.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Tuesday, February 6th. The biopharmaceutical company reported $1.78 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.67 by $0.11. The firm had revenue of $5.95 billion during the quarter, compared to analysts’ expectations of $5.71 billion. Gilead Sciences had a net margin of 17.73% and a return on equity of 50.29%. Gilead Sciences’s revenue for the quarter was down 18.7% on a year-over-year basis. During the same period in the prior year, the company posted $2.70 earnings per share. analysts anticipate that Gilead Sciences, Inc. will post 6.21 EPS for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, March 29th. Investors of record on Friday, March 16th will be issued a $0.57 dividend. The ex-dividend date is Thursday, March 15th. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.52. This represents a $2.28 dividend on an annualized basis and a yield of 2.98%. Gilead Sciences’s dividend payout ratio is currently 65.52%.

COPYRIGHT VIOLATION NOTICE: “Renaissance Group LLC Reduces Holdings in Gilead Sciences, Inc. (GILD)” was first reported by Watch List News and is the property of of Watch List News. If you are reading this piece on another website, it was stolen and reposted in violation of U.S. & international copyright and trademark law. The correct version of this piece can be read at https://www.watchlistnews.com/renaissance-group-llc-reduces-holdings-in-gilead-sciences-inc-gild/1956076.html.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.